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Abstract: Nanoparticle drug delivery vehicles introduce multiple pharmacokinetic processes, with
the delivery, accumulation, and stability of the therapeutic molecule influenced by nanoscale pro-
cesses. Therefore, considering the complexity of the multiple interactions, the use of data-driven
models has critical importance in understanding the interplay between controlling processes. We
demonstrate data simulation techniques to reproduce the time-dependent dose of trimethyl chi-
tosan nanoparticles in an ND7/23 neuronal cell line, used as an in vitro model of native peripheral
sensory neurons. Derived analytical expressions of the mean dose per cell accurately capture the
pharmacokinetics by including a declining delivery rate and an intracellular particle degradation
process. Comparison with experiment indicates a supply time constant, τ = 2 h. and a degradation
rate constant, b = 0.71 h−1. Modeling the dose heterogeneity uses simulated data distributions,
with time dependence incorporated by transforming data-bin values. The simulations mimic the
dynamic nature of cell-to-cell dose variation and explain the observed trend of increasing numbers of
high-dose cells at early time points, followed by a shift in distribution peak to lower dose between 4
to 8 h and a static dose profile beyond 8 h.
Keywords: nanoparticle dosimetry; pharmacokinetics; imaging flow cytometry; nanomedicine; drug
delivery; data-driven models
1. Introduction
The development of nanoparticle-based drug delivery systems introduces a new
pharmacological challenge. Whilst the incorporation of therapeutic molecules within a
carrier matrix is well understood, the unique capability of nanoparticles (NPs) to enter cells
means that the cellular dose of the drug carrier must be tracked and the subsequent delivery
of the drug [1–3]. This is a complex task as drug delivery has many stages [4–6], in which
particles cross multiple biological barriers [7,8] and release their cargo in response to cellular
cues, environmental changes and/or (bio)degradation of the carrier [9,10]. Therefore, the
description of nanoparticle pharmacokinetics requires new approaches that capture the
dynamic nature of the multiple processes that control particle kinetics within cells [11].
The kinetics of drug release from a solid matrix have been exhaustively studied,
providing a comprehensive understanding of this diffusion-driven process [12,13]. This
knowledge has also been widely applied to nanoparticle matrices [14–18]. However, whilst
the kinetics of a molecular cargo is well documented, there are relatively few reports
on the modeling of nanoparticle pharmacokinetics/pharmacodynamics (PK/PD) at the
cellular level. Most studies have focused on the organism level, with physiological-based
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pharmacokinetics (PBPK) in major organs [19,20] or tissue-based NP quantification [21,22].
Although models of the cellular accumulation of NPs and their link to cell death have
been presented [23,24], there remains a need for flexible analytical models that accurately
describe the processes of particle delivery, uptake, and drug release [25].
In this paper, we present mechanistic mathematical expressions and numerical simu-
lations that describe the time dependence of nanoparticle dose at the cellular level. These
accommodate various dynamic processes, controlling particle uptake and stability (degrad-
ability) within the cell, providing a theoretical model for interpreting nanoparticle phar-
macological studies. The delivery system that we choose to model as an exemplar of our
data-driven approach comprises trimethyl chitosan (TMC) NPs as gene delivery vectors de-
signed for neuro-regenerative purposes applied to peripheral neuropathies. The simulated
pharmacokinetics are validated by comparison to the previously reported data from studies
using TMC NPs to vectorize plasmid DNA (pDNA). Chitosan (CH) is a biocompatible
and biodegradable polymer and constitutes a promising gene delivery vector by its ability
to complex and protect genetic material [26,27]. CH efficiency as a gene delivery vector
relies on its molecular weight, which influences the formation of the NPs in terms of size
and complexation capacity for oligonucleotide protection and transfection efficiency. CH
solubility needs to be tuned for physiological conditions by chemical modification, and we
have shown that CH quaternization constitutes a modification that results in increased solu-
bility and transfection efficiency (e.g., trimethyl chitosan (TMC)) [27,28]. The constant fixed
positive charges due to the quaternized amine groups allow nucleic acid complexation at
physiological pH.
Furthermore, modifying the TMC degree of acetylation impacts the charge, solubility,
binding capacity to nucleic acids, cellular uptake, and finally can result in an improved
cellular breakdown of particles and controlled release of cargo. We found that the physic-
ochemical characteristics of TMC–NPs show no significant differences as the degree of
acetylation is changed. TMC was able to complex at least 90% of the pDNA, and TMC-
pDNA NPs showed hydrodynamic sizes below 205 nm, low polydispersity index (PdI,
<0.2), and positive surface charges (≥15 mV). To mimic in vitro conditions, TMC-based NPs
were also evaluated after a 6-fold dilution in complete Dulbecco’s modified eagle medium
(DMEM) at pH 7.4. Under these conditions, NPs’ features remained stable, presenting
average sizes below 191 nm, PdI below 0.24, and positive surface charge (around +10.7 mV).
After exploring the different degrees of acetylation, the best compromise between degrada-
tion kinetics and transfection efficiency was achieved with the TMC with a 16% degree of
acetylation, which showed no cytotoxic effects [28].
The assessment of TMC-NP dose is based on cell images acquired with an imaging
flow cytometer. The advantage of this high throughput imaging technique is that it allows
the analysis of heterogeneous populations and enables access to every individual cell
image. We present the data of Gomes et al. [28] in Figure 1, which shows the measured
TMC-NP fluorescence (assumed to correlate to the cellular dose of pDNA cargo) at set
time points over a 24-h period. Image panels from the imaging cytometer are included.
From these, the evolution of dose as particles internalize to the neuronal cells can be seen.
At the 0.5 h time point, the fluorescence appears as a diffuse signal across the whole of
the cell as particles bind to the cell membrane’s outer surface; some early capture into
cellular vesicles can be seen as punctate spots. After 4 h of exposure, the internalization
process is well advanced, and most of the fluorescence signal comes from high-intensity
spots corresponding to intracellular vesicles. The purpose of our data-driven analyses is
to aid experimenters in the interpretation of time-dependent data such as those shown in
Figure 1, for mean population measures and at the individual cell level.
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Figure 1. Mean YOYOTM-1 fluorescence (p-DNA marker) per cell from dosing study with ND7/23, 
neuronal cells exposed to trimethyl chitosan (TMC16) nanoparticles (data from Gomes et al. [28]). 
The linked panels contain representative bright field and fluorescence images of the cells at each 
measurement time point (image numbers refer to cell reference in the imaging acquisition stream). 
The pixel intensity of the fluorescence channel is scaled by a factor of 10 for the 0.5 h time point to 
enhance visibility. All other images have the same pixel intensity range. 
2. Materials and Methods 
2.1. Cell Culture, Nanoparticle Preparation, and Image Acquisition 
The details of cell culture, formulation of chitosan nanoparticles, exposure studies, 
and measurement of enzymatic degradation of the particles have been reported 
previously by Gomes et al. [28]. A full explanation of the materials and methods used can 
be found in this reference, and summary details are provided here. 
TMC derived from ultra-pure CH was supplied by Kitozyme (40 kDa, Herstal, 
Belgium, lot VIHA0013-157). TMC was purified by filtration and dialysis. The pDNA was 
stained with the cell-impermeant dye YOYOTM-1 that binds and intercalates into the DNA 
(Invitrogen Corp., Waltham, MA, USA). YOYOTM-1 fluorescence increases over a 
thousand-fold when intercalated into double-stranded DNA, and it is used to image 
single DNA molecules. In this regard, the increased intensity of the YOYOTM-1 fluorescent 
image can be translated into a higher number of DNA molecules present and hence a 
higher number of NPs. 
Figure 1. Mean YOYOTM-1 fluorescence (p-DNA marker) per cell from dosing study with ND7/23,
neuronal cells exposed to trimethyl chitosan (TMC16) nanoparticles (data from Gomes et al. [28]).
The linked panels contain representative bright field and fluorescence images of the cells at each
measurement time point (image numbers refer to cell reference in the imaging acquisition stream).
The pixel intensity of the fluorescence channel is scaled by a factor of 10 for the 0.5 h time point to
enhance visibility. All other images have the same pixel intensity range.
2. Materials and Methods
2.1. Cell Culture, Nanoparticle Preparation, and Image Acquisition
The details of cell culture, formulation of chitosan nanoparticles, exposure studies,
and measur ment of enzymatic deg adation of the particles have been reported pr viously
by Go s et al. [28]. A full explanation of the materials and me hods used can be found in
this reference, and summ ry details are provided here.
TMC derived rom ultra-pure CH was supplied by Kitozym (40 kDa, Herstal, Bel-
gium, lot VIHA0013-157). TMC was purified by filtration and dialysis. The pDNA was
stained with the cell-impermeant dye YOYOTM-1 that binds and intercalates into the DNA
(Invitrogen Corp., Waltham, MA, USA). YOYOTM-1 fluorescence incr ases over a thousand-
fold when intercalated into double-stranded DNA, and it is used to image single DNA
molecules. In this regard, the increased intensity of the YOYOTM-1 fluorescent image c n
be translated into a higher number of DNA molecules present and hence a higher number
of NPs.
A sensorial neuron cell line model was used. The ND7/23 (mouse neuroblastoma (N18
tg 2) × rat dorsal root ganglion neuron hybrid) cell line was obtained from ECACC. The
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cells were routinely cultured in a complete DMEM medium (with serum and antibiotics)
and maintained at 37 ◦C in a 5% CO2 humidified incubator. The ND7/23 cells were seeded
into 24-well plates at a cell density of 2 × 104 viable cells per cm2, 24 h prior to incubation
with NPs. TMC-based NPs were prepared at an N/P ratio of 15 with 2 µg of pDNA per
cm2 and incubated with cells from 0.5 h to 24 h, at 37 ◦C. TMC with 16% acetylation
degree (TMC16) was used to prepare the TMC-based NPs. At each time point, cells were
trypsinized and fixed with 4% paraformaldehyde (PFA). Cells were resuspended in PBS at
a density of 105 cells in 50 µL.
Cell images were acquired using an ImageStreamX multispectral imaging flow cytome-
ter (Amnis, Luminex Corporation, Seattle, WA, USA.), collecting 10,000 cells per sample
at 40 ×magnification. A 488 nm wavelength laser was used to excite YOYO®-1, and the
fluorescence images were collected using the 480–560 nm spectral detection channel.
2.2. Nanoparticle Characterization
Nanoparticle hydrodynamic mean diameter and zeta potential were determined using
a Zetasizer Nano Zs (Malvern Instruments, Malvern, UK) following the manufacturer’s in-
structions. NPs were diluted 6 times in Dulbecco’s Modified Eagle Medium (DMEM) with
Glutamax™, 10% (v/v) heat-inactivated (55 ◦C) fetal bovine serum (FBS) and 1% (v/v) peni-
cillin/streptomycin, all supplied by Gibco (Thermo Fisher Scientific, Waltham, MA, USA),
and left to stabilize for 30 min prior to NP size and surface charge determination, using a
high concentration cell (ZEN1010, Malvern Instruments, Malvern, UK). Size measurements
were performed at 25 ◦C at a 173◦ scattering angle in the automatic mode, and the mean
hydrodynamic diameters were determined by cumulant analysis (Z-average mean). The
calculated zeta potential of the NPs was determined by laser Doppler velocimetry (LDV)
and phase analysis light scattering (M3-PALS) at 25 ◦C. The software used was DTS Nano
version 7.11, supplied by the manufacturer (Malvern Instruments, Malvern, UK)
2.3. Nanoparticle Supply Kinetics
To assess the rate of delivery of nanoparticles to cultured cells, the nanoparticle cargo
(DNA) was labeled with the fluorescent probe, YOYO®-1 (Invitrogen Corp., Waltham, MA,
USA) (as described previously [28]) and applied in wells at a 1.9 nM particle concentration.
The fluorescence signal generated by particles on the bottom of the well was measured at
hourly intervals over a 16-h period, using a confocal microscope (integrated intensity of
the bottom of the well with a pinhole of 6 a.u.). The integrated intensity of the bottom of
the well was calculated at each time point using ImageJ software (version 1.52, National
Institutes for Health, Bethesda, MD, USA).
2.4. Analytical Models
A rate equation analysis was used to derive expressions for the time-dependent signal
per cell arising from labeled nanoparticles (signal assumed to be proportional to particle
number). Different cases are presented, dependent upon the specific conditions assumed
for particle supply and loss processes.




where S is the measured dose signal (arbitrary units), and a is the accumulation rate






S = at (3)
There is a linear increase in signal at a rate, a.
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A2. Nanoparticle accumulation from an infinite supply but with a dose loss mechanism:
dS
dt
= a− bS (4)
where b is the rate of signal loss per unit metric.∫ S
0
1











The (1 − exp) term produces a non-linear signal increase to a saturation level equal to
a/b. This maximum reflects a steady state in which the number of particles accumulated
per unit time equals the number lost.
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A complex function with countervailing terms describing signal growth/decay driven
by particle accumulation/loss.
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3. Results
3.1. Population-Averaged Pharmacokinetics
Our starting point for the analysis was estimating the mean level of particle accumula-
tion across a cell population. The complexities of biological heterogeneity were avoided by
treating cells as a homogenous group to derive a population average dose. We aimed to
identify the key generic processes of dose accumulation and intra-cellular transformation.
The focus is on process kinetics. It is the temporal evolution of dose that we wish to describe.
Thus, the analysis described the outcome rather than the specific biological mechanism at
play (e.g., endocytosis, diffusion, etc.). Even under the constraint of a population mean,
the kinetics of particle supply and trans-membrane transport, together with the instability
of degradable nanoparticles, present a multiplicity of potential system dynamics. The
analytical expressions presented in the methods section describe three possible scenarios:
1. Particle uptake at a constant rate (A1)
The simple situation of stable particles and a constant internalization rate for cellular
uptake.
2. Particle uptake with a limiting process to supply or accumulation (A2 and A3)
This introduces the possibility of bottlenecks or loss mechanisms that operate to limit
the nanoparticle dose. Two possible situations are considered, a rate reduction due to
limitations in particle supply or a loss process that reduces the cellular dose post uptake
(e.g., nanoparticle disassembly or exocytosis).
3. Particle uptake with a limiting process to supply and accumulation (A4)
The case for accumulation of particles in the presence of a bottleneck in supply and a
cellular loss in dose was considered.
The time-dependent accumulation predicted by each of these models is shown in
Figure 2. In the ideal case of an unlimited supply of NPs and a constant internalization rate,
there is a linear increase in particle number (fluorescence signal) over time. This is seldom
achieved as mechanisms that limit the maximum dose result in a mean number of particles
per cell that rises and then saturates to a fixed level. The time-dependent dose curve follows
a [1 − exp(−κt)] form, and this kinetic has been observed for various limiting processes.
In NP assays, supply is often limited as a fixed environmental reservoir of particles is
significantly depleted by transfer to cells [29,30]. This form of saturation in delivered dose
is also seen for drug delivery from a solid matrix [15,31], where similar limitations due to
a depleting supply take effect. When the dose limitation is due to loss from the cell, the
saturation level reflects the situation where rates of particle internalization and loss are
equal. This type of loss process will arise when there is intra-cellular loss, e.g., in the case
of biodegradable particles [32], or can result from particle expulsion, e.g., such as occurs
when partitioning into daughter cells upon cell division [23] or exocytosis [33,34]. Finally,
the loss mechanism could relate to a lack of internalization rather than loss of particles per
se. The kinetics of binding and release of ligands with cell surface receptors can follow a
[1 − exp(−κt)] form as available binding sites become saturated [35–37]. In the presence
of supply limitations and particle loss, three processes drive the system dynamic—arrival
from a depleting supply reservoir, internalization, loss from the cell, and hence we see
an additional inflection in the accumulation curve. The cellular loss of a finite supply of
particles drives the dose to zero over long periods.
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Figure 2. Schematic of the time-dependent cellular dose of nanoparticles under different conditions;
i. a cumulation at a constant rate from an infinite particle reservoir (solid line); ii. a cumulation with
a supply rate limitation or particle loss from the cell (dashed line); iii. accumulation with supply rate
limitation and particle loss from the cell (dotted line).
These fundamental processes shaping the particle dose curve provided preliminary
analysis for an NP dosing study. It highlighted limitations to the long-term cellular a cu-
mulation of particles and indicated the proce s time-constants involved. As an example,
the data from the study of Gomes et al. [28] is shown in Figure 3 (fluorescently labeled
TMC16 particles—16% acetylation, incubated ith 7/23, neuronal cel line). The time-
dependent fluorescence of these trimethyl chitosan particles exhibited multiple dynamics
with initial a cumulation followed by reduction to a stable level within 24 h (Figure 3A).
The study used biodegradable nanoparticles, specifica ly designed to di sociate when in
cellular vesicles. There was, therefore, an imposed particle lo s echanism. This proce s
alone would l onotonical y increasing dose that saturates over time (Figure 2 and
Materials and Methods, A2, Equation (6)). It is clear, therefor , that other proc sses were at
play here. The kinetics of the particl degradation were captured using a competition assay
in which the parti les were incubat d with lysozyme and a fluorogenic s bstrate [28,38]
(Figure 3B). The action of t e enzyme led to the break own of the chitosan particles result-
ing in a decrease i the fluorescent signal. Notably, there was not a complete loss of the
signal, and we attribute the fixed baseline to a stopping point, beyond which particles do
not undergo further enzymatic degradation. This limitation to the action of the lysozyme
has been attributed to the loss of acetylated units during degradation leading to a lack of
binding sites for the enzyme once the chitosan reaches a baseline molecular weight [28].
Fitting the time-dependent fluorescence data using an exponential decay model (Materials
and Methods, A2) indicated a rate-constant, b for the particle degradation of 0.71 per hour
and a fixed, time-independent signal equal to 0.38 of the maximum value. To assess the
supply kinetics TMC-NP with a fluorescently labeled DNA cargo were introduced to the
cell culture wells. The fluorescence signal from the bottom of the well was then measured
in the absence of cells (Figure 3C). This provided a measure of the supply rate, indepen-
dent of cell internalization processes. The signal’s unambiguous saturation, indicating
complete cessation of particle supply from the suspension, with a rise-time constant, τ of 2
h (Materials and Methods, A3, Equation (10)).
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predictor of particle dose kinetics. It supports the hypotheses implied in forming the ana-
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cellular level for a single NP exposure concentration. Thus, while prediction of the mean 
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Figure 3. (A). Mean fluorescence per cell from dosing study with ND7/23, neuronal cells exposed
to trimethyl chitosan (TMC16) nanoparticles (data from Gomes et al. [28], solid line: fit curve using
the analytical function in Methods—A4, error bars indicate s.e.m.). (B). fluorescence from nanopar-
ticles undergoing enzymatic degradation (data from Gomes et al. [28], solid line: e−bt fit curve).
(C). accumulation of particle fluorescence signal from the base of the culture well (solid line:
[1 − e−t/τ] fit curve).
The combined action of this supply bottleneck and the cellular degradation of nanopar-
ticles is sufficient to explain the time-dependent dose profile. Substitution of the measured
rate constants for these processes into the analytical functions provides an accurate repre-
sentation of the mean fluorescence per cell (Materials and Methods—A3, Equation (10) used
for the stable fluorescence signal and A4, Equation (15) for the biodegradable fraction, in a
38:62 ratio). There is a single fit-variable of the accumulation rate, a, which scales the model
curve relative to the dataset (Figure 3A). The strong correlation between the analytical pre-
diction and the measurement data confirms the model’s validity as a predictor of particle
dose kinetics. It supports the hypotheses implied in forming the analytical equations.
3.2. Single Cell Pharmacokinetics
Biological heterogeneity ensures that there will be a variation of acquired dose at
a cellular level for a si gle NP exposure concentration. Thus, while prediction of the
mean dos pe cell is informative, a detailed understanding of particle accumulation
requires analysis and quantifica ion of the cell-to-cell dose variability. The predominant
experimental techn que for studying he cellular dose of particulates is flow cytometry
which naturally captures a d visua izes measurement variance using histograms. This
suggests similar approaches to the modeling of single-cell pharmacokinetics, with a focus
on dat distributions. This wou d all w direct interpretation of simulations and an i tuitive
unders anding of their import as they are pr sented in the sa e format as the experimental
data. The data-directed approach also provided a novel route to model construction as the
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time-dependent evolution of the data construct could be simulated rather than the data
itself, i.e., the changing shape of the histogram is predicted, not the values of the measured
variable—individual cellular dose. It is this direct simulation of the cytometry histogram
that we adopted. The principles of our approach are demonstrated in Figure 4, which
depicts the algorithmic transformations for a selected subset of bins.
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Figure 4. Schematic of histogram evolution to simulate particle accumulation and biodegradation.
(A). Initial Poisson PDF generated at t0. (B). Continued NP accumulation within cells of bin 10 during
t to t + ∆t shown. (C). Reduction in dose by a fraction η, due to NP degradation. (D). final summing
of dose at t + ∆t. The example is shown for a limited sample of 3 distributions, corresponding to
original bin indices 9, 10, and 11, at t0.
An initial (t = t0) distribution of dose per cell was created using a probability dis-
tribution function (PDF) to reflect the heterogeneity of uptake per unit timestep, ∆t [39]
(Figure 4A). The exact fitting of experimental data requires modeling variance in cell area
and particle arrival rate, resulting in an asymmetrical, over-dispersed PDF [40]. Here we
took a simplified approach and adopted a Poisson distribution function, with the rate
variable, λ, representing the mean dose accumulated over ∆t. Although this did not match
measured cytometry histograms exactly, it provided the important accounting of variability
in particle uptake. It allowed efficient and plausible simulation of the time-dependent
evolution of histogram shape and the overall mean value of dose.
The cell dose’s time dependence is modeled by manipulating the histogram bins to
simulate the effect of continued dose accumulation and the ensuing biodegradation within
cell vesicles. Over a timestep (t0→ t0 + ∆t), cells in bin i with dose Di will continue to accu-
mulate particles. However, due to the heterogeneity of uptake, there will be a dispersion in
the dose as t is sub-set of cells, with identical dose at t0, gain differin numbers of particles.
This is simulated by replacing the single bin-value of Ni cells of dose Di, with the Poisson
dose-accumulation PDF, offset to a mean of (Di + λ) d with a normalized rea of Ni to
conserve cell number (Figure 4B). The biodegradation of nanop rticles leads to a fractional
loss, η in dose over the period (η = e−b∆t), which is accounted for by a leftwards shift of
the histogram with new bin values of η.i units (Figure 4C). The total dose distribution is
calculated from implementing the above procedure for each bin (i = 1:n), followed by the
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summation of the n histograms produced (Figure 4D). To simulate the decrease in particle
uptake rate stemming from depletion of the supply reservoir, the Poisson distribution rate
is implemented as a time-dependent parameter, λ(t), exponentially decreasing according to
the measured time constant, τ (see Figure 3C).
The net result of these dose-determining processes is increasing or decreasing cell
number counts across the histogram bins over time. The signature of the pharmacokinetics
can thus be seen in the changing shape of the distribution. A comparison of the data-
histogram simulation to experimental distributions is shown in Figure 5 for cells incubated
with TMC16 particles over a 24-h period.
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to a lowered dose per cell. This manifests in the distribution as reduced cell numbers in the
high dose bins and increasing numbers in the low dose bins. This shifts the peak and skews
the shape of the distribution leftwards along the x-axis. While particle arrival at the cell
does occur beyond the 8-h time point, it is minimal (see Figure 3C), and the fluorescence of
previously acquired particles has decayed to the baseline value by this time (see Figure 3B).
The influence of particle biodegradation and supply on the overall dose kinetic is complete
by the 8-h mark. So there is little further change in the histogram beyond this point as
it represents a stable dose within cells that are no longer exposed to particles from the
surrounding medium. This agrees with previous measurements of chitosan internalization
in this cell line [28].
4. Discussion
The development of active nanosystems, designed to deliver targeted interaction with
selected cell types and exploit intra-cellular processes to release a drug cargo, greatly adds
to the complexity of their pharmacokinetics. This necessitates a reappraisal of standard
assumptions on the scalability of exposure and dose, encapsulated in commonly applied
rules such as Haber’s law [29,41]. The multiple stages and biological interactions of
nano-pharmacology led to a dose-time relationship markedly non-linear and potentially
non-monotonic. These functional complexities may be viewed as confounding factors to
the understanding of pharmacology. However, the very fact that the various particle-cell
interactions shape the dose profile means that their signature may be extracted from the
data. In this paper, we present analytical functions suitable to describing the mean dose-
time curve for cell populations. The set of equations provided is an easily adopted tool
to identify key processes at play and provide a first approximation of dose kinetics in an
experiment from standard measures of mean cell dose. The equations describe supply
variation and loss of intra-cellular dose in cells exposed to multi-stage NP drug-delivery
systems. The model parameters: a (dose accumulation-rate) and b (intra-cellular dose
loss-rate) describe generic processes common to most NP exposure conditions. They are
agnostic to the specific mechanisms at play, i.e., we do to attempt to describe how NPs enter
the cell or how they may be transformed by cellular metabolism. We aimed to identify the
signature of kinetic processes within time-dependent data and provide the experimenter
with tools to aid the understanding of these patterns.
The validity of these analytical models is demonstrated by their application to a study
of the uptake of biodegradable chitosan particles by neuronal cells. This specific example
highlights limitations to the drug supply due to the depletion of NP concentration in the
cellular environment and the loss of particles once internalized. The correspondence of the
mathematical prediction to the data (see Figure 3A) suggests that in this case, the quantified
degradation of particles by cell vesicle enzymes is sufficient to account for the reduction in
mean dose with no apparent contribution from particle exocytosis.
The interpretation of cellular pharmacokinetics is usually based on dose histograms
from flow cytometry. From the point of view of applicability, the ideal model should
simulate this primary experimental data and mimic the cell-to-cell heterogeneity inherent
in measured dose distributions. We adopt this premise and bring a fresh approach to
cell modeling by directly simulating the data construct rather than the measurement
variable itself—the time-dependent rise and fall in cell populations of a specified dose is
modeled by direct manipulation of bins in a simulated histogram. Modeling the data plot
in this way guarantees relevance to the experiment and facilitates interpretation of the
simulation results. It also restricts the computational task to implementing mathematical
transformations on a set of distribution bins. This is simpler than the commonly used
techniques. A multiplicity of rate equations is used to describe heterogeneous cell sub-
groups, or a stochastic, ‘biological-noise’ term is included within a single global rate
equation to account for process variability [42–44].
As nanomedicine has developed, there has been a continual advancement in metrology
techniques for assessing NP dose, often in response to identified gaps in current capa-
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bility [45,46]. The evolution of multi-functional, smart nanoscale drug delivery systems
that interact with endogenous biological processes presents a challenge to measurement
techniques. The important additionality here is that for these highly dynamic systems,
the pharmacokinetic process must be quantified and pharmacological dose. The methods
presented in this paper provide easily adopted approaches to this challenge, developed as
data-driven tools to ensure ready interpretation of experimental results.
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